Show simple item record

dc.contributor.advisorHutt, Peter Bartonen_US
dc.contributor.authorLazar, Simonen_US
dc.date.accessioned2012-07-06T21:59:30Z
dc.date.issued2006en_US
dc.identifier.citationProgress Report: A Comprehensive Evaluation of the FDA's Battle against Counterfeit Drugs (2006 Third Year Paper)en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:8965600
dc.description.abstractAlthough drug counterfeiting is a major issue in many regions of the world, the U.S. drug supply is generally safe due to extensive federal and state oversight and steps taken by drug manufactures, distributors, and pharmacies to prevent drug counterfeiting. The U.S., however, now faces an increasing counterfeit drug threat due to advances in counterfeiting technology and increased financial incentives for criminals to introduce counterfeit drugs into the U.S. drug supply. The first half of this paper describes the threat posed by counterfeit drugs, discusses the scope of the counterfeit drug problem, explains how counterfeit drugs may be introduced into the U.S. drug supply, and discusses past efforts taken by U.S. authorities to secure the drug supply. The second half of this paper analyzes the FDA’s 2004 recommendations on how to best fight the counterfeit drug threat, addressing the merits of the FDA’s recommendations as well as the FDA’s success in implementing such recommendations thus far.en
dc.language.isoen_USen
dash.licenseLAAen_US
dc.subjectFood and Drug Lawen
dc.subjectcounterfeit drugsen
dc.titleProgress Report: A Comprehensive Evaluation of the FDA's Battle against Counterfeit Drugsen
dc.typePaper (for course/seminar/workshop)en_US
dc.date.available2012-07-06T21:59:30Z
dash.authorsorderedfalse


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record